Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 601–700 of 3,116
Delko, T., Kraljević, M., Lazaridis, I. I., Köstler, T., Jomard, A., Taheri, A., Lutz, T. A., Osto, E., & Zingg, U. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-10907-7 · Cited by 13
Contemporary treatment options in heart failure with preserved ejection fraction
Peikert, A., & Solomon, S. D. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae201 · Cited by 15
Khorsandi, M., Blumenthal, R. S., Blaha, M. J., & Kohli, P. (2024) · Clinical Cardiology · doi:10.1002/clc.24284 · Cited by 14
Swift, D. L., Ross, L. M., Laddu, D. R., Conroy, M. B., German, C. A., Evangelista, L. S., Marvel, F. A., Jerome, G. J., on behalf the American Heart Association Council on Lifestyle and Cardiometabolic Health, Council on Cardiovascular and Stroke Nursing, et al. (2026) · Circulation · doi:10.1161/cir.0000000000001441 · Cited by 13
Picoli, C. C., Tsibulnikov, S., Ho, M., DeMambro, V., Feng, T., Eltahir, M., Le, P. T., Chlebek, C., Rosen, C. J., Ryzhov, S. V., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00521.2024 · Cited by 13
Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Pandey, A., Kitzman, D. W., Chinnakondepalli, K., Patel, S., Borlaug, B. A., Butler, J., Davies, M. J., Shah, S. J., Verma, S., Rönnbäck, C., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102610 · Cited by 18
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 19
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 19
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 34
Mancusi, C., Basile, C., Spaccarotella, C., Gargiulo, G., Fucile, I., Paolillo, S., Gargiulo, P., Santoro, C., Manzi, L., Marzano, F., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00629-1 · Cited by 15
Siddiqui, H. F., Ali, D., Sajid, M., Qureshi, S., Siddiqui, H., Hasan, A., Ripley, D. P., Ahmed, R., & Waqas, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70123 · Cited by 22
Assessing the state of obesity care: Quality, access, guidelines, and standards
Kaplan, L. M., Apovian, C. M., Ard, J. D., Allison, D. B., Aronne, L. J., Batterham, R. L., Busetto, L., Dicker, D., Horn, D. B., Kelly, A. S., et al. (2024) · Obesity Science & Practice · doi:10.1002/osp4.765 · Cited by 20
Dietary restriction in aging and longevity
Schmauck‐Medina, T., Lautrup, S., Francesco, A. D., Mitchell, S. J., Clemmensen, C., Partridge, L., Roth, G. S., Anderson, R. M., Mattison, J. A., de Cabo, R., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01091-5 · Cited by 28
Smolderen, K. G. E., Mena‐Hurtado, C., Zhao, Z., Michalak, W., Faurby, M. D., Smolarz, B. G., Kosiborod, M., Song, J., Chen, Y., Boland, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70080 · Cited by 18
Monitoring Report: GLP-1 RA Prescribing Trends - September 2026 DataPreprint
Gratzl, S., Gilbert, K. M., Holler, E., Vachon, M. S., Masters, N. B., Wallen, Z. D., & Cartwright, B. M. G. (2025) · medRxiv · doi:10.1101/2025.03.06.25323524 · Cited by 16
Karakasis, P., Koufakis, T., Patoulias, D., Barkas, F., Klisic, A. N., Mitrović, M., Doumas, M. N., Παπάνας, Ν., & Popovic, D. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15979 · Cited by 20
Asia at the Epicenter of the Global Cardiometabolic Shift
Khanna, S., Gan, G. C. H., Sindone, A. P., Tromp, J., Butler, J., Foo, R., Nerlekar, N., & Bhat, A. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.001 · Cited by 19
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Bensignor, M. O., Arslanian, S. A., & Vajravelu, M. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001365 · Cited by 20
Zhang, Y., & Yao, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02442-8 · Cited by 16
Obesity-Related Kidney Disease: A Growing Threat to Renal Health
León-Román, J. C., López-Martínez, M., Esteves, A., Ciudin, A., Núñez-Delgado, S., Álvarez, T., Lecube, A., Rico-Fontalvo, J. E., & Soler, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146641 · Cited by 19
Żera, T., Paleczny, B., Siński, M., Conde, S. V., Narkiewicz, K., Ponikowski, P. P., Paton, J. F. R., & Niewiński, P. (2025) · The Journal of Physiology · doi:10.1113/jp285081 · Cited by 15
Hasebe, M., Su, C., Keidai, Y., Minamino, H., Yabe, D., Inagaki, N., & Yoshiji, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70121 · Cited by 16
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 17
Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
Lau, D., & Gamble, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15459 · Cited by 14
Hasselbalch, R. B., Andréa, M. K., Nolsøe, C. V., Hindborg, M., Yazdanfard, P. D. W., Sørensen, K. K., Blomberg, S. N. F., Christensen, H. C., Graff, C., Denholt, C. S., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101398 · Cited by 19
Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
Spinelli, K. J., Oakes, A. H., Chiu, S., Imboden, M. T., Miller, A. B., Jain, S., & Gluckman, T. J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100100 · Cited by 16
Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2746 · Cited by 14
Managing obesity in adults with type 1 diabetes
Campos, A., Gutiérrez, R. D. J. R., Galindo, R. J., McCoy, R. G., & Andrade, M. D. H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111983 · Cited by 14
Zamanian, N., Imani, H., Talebi, S., Rahimlou, M., Khosroshahi, R. A., & Mohammadi, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177966 · Cited by 19
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
“Semaglutide has also been approved for reducing major cardiovascular events in adults with over-weight or obesity [36].”
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Ruseva, A., Dabbous, F. M., Ding, N., Fabricatore, A. N., Huse, S., Michalak, W., Nordstrom, B. L., Hartaigh, B. Ó., Zhao, Z., & Umashanker, D. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2482274 · Cited by 17
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
Toth, P. P., & Banach, M. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae057 · Cited by 17
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
Heart failure and obesity: novel insights leading to new treatment paradigms
Meems, L. M. G., van Veldhuisen, D. J., Sattar, N. A., & Lee, M. M. Y. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01190-7 · Cited by 20
Maremmani, M., Ebrahimi, R., Centola, M., Achilli, F., Capone, V., Bossone, E., Templin, C., & Vece, D. D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02592-0 · Cited by 13
CKDs at the Crossroads: From Failures to Future Therapies
Wehbe, F., Elliott, M., & Levin, A. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.050 · Cited by 17
Elhag, W., & Ansari, W. E. (2025) · Obesity Surgery · doi:10.1007/s11695-024-07654-y · Cited by 15
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 15
Castaneda, R., Bechenati, D., Tama, E., Gutiérrez, R. D. J. R., Espinosa, M. A., Villamarin, J. L., Rajjo, T. I., Acosta, A. J., Faubion, S. S., SHUFELT, C. L., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(25)00145-1 · Cited by 17
Ostrominski, J. W., Solomon, S. D., & Vaduganathan, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae414 · Cited by 16
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Gami, A., Blumenthal, R. S., McGuire, D. K., Sarkar, S., & Kohli, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034053 · Cited by 17
Matsumoto, C., Nagai, M., Shinohara, K., Morikawa, N., Kai, H., & Arima, H. (2025) · Hypertension Research · doi:10.1038/s41440-025-02240-w · Cited by 15
Goodheart, R. H., & Ayonrinde, O. T. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.009 · Cited by 21
Anti‐obesity Medications: Ethical, Policy, and Public Health Concerns
Klitzman, R., & Greenberg, H. (2024) · The Hastings Center Report · doi:10.1002/hast.1588 · Cited by 17
Patoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
Semaglutide and heart failure: Updated meta-analysis.
Barbagelata, L., Masson, W. M., Lobo, M., & Bluro, I. M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102721 · Cited by 13
Bagheri, M., Tanrıverdi, K., Iafrati, M. D., Mosley, J. D., Freedman, J. E., & Ferguson, J. F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155955 · Cited by 17
See, X. Y., Xanthavanij, N., Lee, Y.-C., Ong, T. E., Wang, T. H., Ahmed, O., Chang, Y., Peng, C.-Y., Chi, K.-Y., Chang, Y., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00803-2024 · Cited by 13
Expanding applications of therapies based on GLP1
Drucker, D. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01066-9 · Cited by 18
The effect of obesity interventions on male fertility: a systematic review and meta-analysis
Peel, A., Lyons, H. E., Tully, C. A., Vincent, A. D., Jesudason, D. R., Wittert, G., & McPherson, N. O. (2025) · Human Reproduction Update · doi:10.1093/humupd/dmaf025 · Cited by 19
Tuccinardi, D., Zilich, R., Ponzani, P., Musacchio, N., Manicardi, V., Rocca, A., Pontremoli, R., Fioretto, P., Muscarà, A., Cianni, G. D., et al. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00251-7 · Cited by 12
“Finally, GLP-1RAs offer anti-inflammatory and cardioprotective benefits, potentially independent of weight loss [34], and should be considered for patients with lower BMI, countering bias in current prescribing practices.”
Evolution and Future of Stroke Trials
Broderick, J. P., & Mistry, E. A. (2024) · Stroke · doi:10.1161/strokeaha.123.044265 · Cited by 12
Zomer, E., Zhou, J., Nelson, A. J., Sumithran, P., Nanayakkara, S., Ball, J., Kaye, D. M., Liew, D., Nicholls, S. J., Stub, D. A., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae063 · Cited by 12
Glucagon-like peptide-1 receptor agonism and end-organ protection
Daniels, S. J., Karlsson, C., Schrauwen, P., & Parker, V. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.002 · Cited by 20
McDermott, M. M., Kadian‐Dodov, D. L., Aronow, H. D., Beckman, J. A., Bolden, D. M., Castro‐Dominguez, Y., Creager, M. A., Criqui, M. H., Goodney, P. P., Gornik, H. L., et al. (2025) · Vascular Medicine · doi:10.1177/1358863x251330583 · Cited by 13
Gomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 18
Sambola, A., Campuzano, R., Castro, A., Goya, M., Coronado, P., Fernández-Olmo, R., Tablado, M. Á. M., Ortiz-Cortés, C., Ortolà, X., Pallarés‐Carratalá, V., et al. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.01.015 · Cited by 13
Guo, J., Song, Z., Wang, S., Yao, D., Yu, H., Fu, M., Chen, M., Jiang, W., Zhang, Y., Wu, S., et al. (2025) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014069 · Cited by 22
Obesity and climate change: co-crises with common solutions
Behrens, P., Champagne, C. M., Halford, J. C. G., Moodie, M., Proietto, J., Rutter, G. A., Samaras, K., & Holly, J. M. P. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1613595 · Cited by 14
Chi, K.-Y., Song, J., Desphande, S., Lee, P., Soni, A., Gonzales-Uribe, A., Lessa, Y., Morgan, A. A., Chang, Y., Lin, Y.-S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17541 · Cited by 14
Miranda, S., Choudhari, J., Chauhan, N., & Parmar, M. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177953 · Cited by 17
Effects of weight-loss interventions on bone health in people living with obesity
Paccou, J., Gagnon, C., Yu, E. W.-Y., & Rosen, C. J. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf135 · Cited by 18
Hansen, M. K., Olesen, K. K. W., Gyldenkerne, C., Thrane, P. G., Stødkilde-Jørgensen, N., Mortensen, M. B., & Mæng, M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.029 · Cited by 13
Beaudrey, T., Bedo, D., Weschler, C., Caillard, S., & Florens, N. (2025) · Diagnostics · doi:10.3390/diagnostics15070802 · Cited by 21
GLP-1 RA for cardiometabolic risk reduction in obesity – How do we best describe benefit and value?
Kumar, S., & Blaha, M. J. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100682 · Cited by 13
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
Ard, J. D., Neeland, I. J., Rothberg, A. E., Chilton, R. J., de Luis, D., Cohen, S. S., & Johansen, O. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15392 · Cited by 12
“…larger weight loss, as well as influence CV risk factors more profoundly, 32,33 and even lead to a reduction in ASCVD events in people with obesity, 34 a long-term study comparing weight loss via caloric restriction through an MRP or a glucagon-like peptide-1 receptor analogue, for ASCVD outcomes…”
BackgroundGuy, A., Azab, A. N., Liberty, I. F., Afawi, Z., Alhoashla, A., & Abu Tailakh, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15436 · Cited by 12
“46 In our study, an increase in the enzyme amylase was observed among liraglutide users, potentially indicating a pancreatic side effect (however, no increase in lipase was found).”
BackgroundNew pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 18
Semaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 36
Bułdak, Ł., Bołdys, A., Skudrzyk, E., Machnik, G., & Okopień, B. (2024) · Metabolites · doi:10.3390/metabo14100554 · Cited by 17
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Shahid, I., Khan, M. S., Butler, J., Fonarow, G. C., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10481-7 · Cited by 16
(2024) · doi:10.1101/2024.12.09.24318574 · Cited by 85
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease
Rennert‐May, E., Manns, B., Clement, F. M., Spackman, E., Collister, D., Sumner, G., Leal, J. R., Miller, R. J. H., & Chew, D. S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.09.025 · Cited by 21
Obesity and Atrial Fibrillation: From Mechanisms to Treatment
Dziano, J. K., Ariyaratnam, J., Middeldorp, M. E., Sanders, P., & Elliott, A. D. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.003 · Cited by 17
Kassab, M., Khraishah, H., Thrapp, A. D., Abohashem, S., Vijay, A., Rentz, T., Song, D.-R., Spicer, G. L. C., Goudot, G., Chowdhury, M. M., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag060 · Cited by 18
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W. M., Lobo, M., Barbagelata, L., Cobo, A. L., & Nogueira, J. P. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.01.001 · Cited by 26
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection
Wang, X., Qi, M., Yang, L., Yang, L., Wang, X., Zhang, F., Cui, Y., Wang, D., Wang, Y., & Lv, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1614726 · Cited by 20
Fath, A. R., Aglan, A., Maron, M. S., Phillips, J. S., Maron, B. J., & Rowin, E. J. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133082 · Cited by 11
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 14
GLP1R Gene Expression and Kidney Disease Progression
Triozzi, J. L., Yu, Z., Giri, A., Chen, H., Wilson, O. D., Ferolito, B. R., Ikizler, T. A., Akwo, E. A., Robinson‐Cohen, C., Gaziano, J. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.40286 · Cited by 11
The Impact of Obesity on Cardiovascular Diseases: Heart Failure
Alansari, H., Lazzara, G. E., Taha, M. B., & Gorthi, J. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1511 · Cited by 18
Ostrominski, J. W., & Powell‐Wiley, T. M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01182-3 · Cited by 15
Goubar, T., Goubar, C., Fenton‐Lee, D., Stefanidis, A., Macdonald, P. S., & Rushworth, R. L. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07699-7 · Cited by 12
Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review
Javaid, A., Hariri, E. H., Özkan, B., Lang, K., Khan, S. S., Rangaswami, J., Stone, N. J., Blumenthal, R. S., & Ndumele, C. E. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100089 · Cited by 15
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Hamblin, P. S., Earnest, A., Russell, A. W., Talic, S., Zomer, E., & Zoungas, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15893 · Cited by 13
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., Hussain, S. A., & Hennige, A. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16167 · Cited by 12
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
Glucagon-like peptide-1 receptor agonists and the eye
Zhang, D. L., & Finn, A. P. (2025) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001137 · Cited by 15
Evén, G., Stenfors, T., Jacobson, S. H., Jernberg, T., Franzén‐Dahlin, Å., Jäghult, S., Kahan, T., & Spaak, J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae331 · Cited by 14
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
